Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Megan Haggan 29/09/2020

Debbie Rigby takes a look at the latest in research news Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure The EMPEROR-Reduced Trial compared empagliflozin (10 mg once daily) or placebo (in addition to recommended therapy) in 3730 patients with heart failure and an ejection fraction of 40% or less. Results show a lower risk

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Medics to ‘fight’ Doctor of Pharmacy title

For a century in Australia, Doctors also had a double bachelor and no PhD

William Stevenson

No products available

In a busy pharmacy you could easily spend an hour a day talking to patietns about shortages, following up with…

Ben Wishaw

No products available

60DD doesn’t help with the shortage like Duodart

Paul Lai

Doctor of Pharmacy addresses anomaly

I thought it was from 1 Jan, not 1 July.

taron p

Research Roundup

Previous ‘Very, very lengthy delay’ torpedoes unfair dismissal case

Next COVID-19 and conduct: social media warning

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous ‘Very, very lengthy delay’ torpedoes unfair dismissal case

Next COVID-19 and conduct: social media warning

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.